Synergistic growth inhibition of prostate cancer cells by 1α,25 Dihydroxyvitamin D3 and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A
- 5 April 2001
- journal article
- Published by Springer Nature in Oncogene
- Vol. 20 (15) , 1860-1872
- https://doi.org/10.1038/sj.onc.1204269
Abstract
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.Keywords
This publication has 49 references indexed in Scilit:
- Butyrate-inducible elements in the human γ-globin promoterExperimental Hematology, 2000
- Coactivator and corepressor complexes in nuclear receptor functionCurrent Opinion in Genetics & Development, 1999
- Metabolism of 1α,25(OH)2D3 and its 20-epi analog integrates clonal expansion, maturation and apoptosis during HL-60 cell differentiationMolecular and Cellular Endocrinology, 1999
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- In Vivo Analysis of the Major Exocytosis-sensitive Phosphoprotein in Tetrahymena The Journal of cell biology, 1997
- AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian CancerScience, 1997
- Effects of retinoid X receptor-selective ligands on profileration of prostate cancer cellsThe Prostate, 1997
- Vitamin D receptor expression is required for growth modulation by 1α,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31The Journal of Steroid Biochemistry and Molecular Biology, 1996
- Labelling DNA strand breaks with BrdUTP. Detection of apoptosis and cell proliferationCell Proliferation, 1995
- Sodium butyrate (SB) augments the effects of 1,25 Dihydroxyvitamin D3 (1,25(OH)2D3) on neoplastic and osteoblastic phenotype in clonal rat osteosarcoma cellsBiochemical and Biophysical Research Communications, 1984